Skip to content

Low serum level of epidermal growth factor in chronic ketamine users.

Minling Zhang, Hongbo He, Yuping Ning, Yi Ding, Xiaoyin Ke, Daping Wang, Xuefeng Deng, Ni Fan

Human Psychopharmacology: Clinical and Experimental May 2018 DOI: 10.1002/hup.2656 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case-control study Peer reviewed
Sample size 107
Population Chronic ketamine users and healthy control subjects
Measures Positive and Negative Syndrome Scale, Beck Depression Inventory, Beck Anxiety Inventory
Topics Ketamine Esketamine
Keywords Epidermal growth factor Serum
Key findings Serum EGF levels were significantly lower in chronic ketamine users than in healthy controls (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml). Among users, EGF was negatively correlated with average daily ketamine dose and positively associated with PANSS positive symptom scores. The authors propose EGF may contribute to the pathophysiology of ketamine-related disorders.

Abstract

Growth factors play an important role in brain development. Whether epidermal growth factor (EGF) plays a role in the pathophysiology of ketamine related disorders is unexplored. In this study, we examined the serum levels of EGF in chronic ketamine users as compared with healthy controls. The possible correlation between serum EGF levels with the demographic, ketamine use characteristics and psychopathological symptoms were analyzed. Sixty-seven chronic ketamine users and 40 healthy subjects were recruited. Serum EGF levels were measured by enzyme-linked immunosorbent assay. Psychopathological symptoms were assessed using Positive and Negative Syndrome Scale, Beck Depression Inventory and Beck Anxiety Inventory. The serum level of EGF in the chronic ketamine users was significantly lower than that of healthy subjects (22.34 ± 4.81 pg/ml vs. 87.10 ± 2.96 pg/ml, F = 15.169, p < 0.01). The serum EGF level was negatively correlated with the current average dose of ketamine consumption per day of use (p = 0.015), and positively associated with the Positive and Negative Syndrome Scale positive symptom score (p = .022). Serum level of EGF decreased in chronic ketamine users compared with healthy subjects, which may play a role in the pathophysiology of ketamine related disorders.

Comparable studies

Other observational and cohort studies on ketamine, most cited first.

Study Year Design Participants
Taming the Ketamine Tiger Volunteers from a prison population 2010 Observational study n = 20
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin Humans 2017 Observational study
Disruption of Frontal–Parietal Communication by Ketamine, Propofol, and Sevoflurane Surgical patients undergoing induction of anesthesia with intravenous ketamine 2013 Observational cohort n = 30
Do the dissociative side effects of ketamine mediate its antidepressant effects? Treatment-resistant inpatients with major depressive disorder or bipolar disorder 2014 Observational cohort n = 108
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder Patients with treatment-resistant major depressive disorder 2012 Observational cohort n = 30

Citations in the library

Explore topics